Source:http://linkedlifedata.com/resource/pubmed/id/19537528
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2009-6-22
|
pubmed:abstractText |
The study was designed to compare the rate and extent of absorption of two fixed dose combination tablet formulations of lopinavir (CAS 192725-17-0) and ritonavir (CAS 155213-67-5). This bioequivalence study was conducted using a standard preparation as reference and a generic alternative as test in 72 adult healthy volunteers within 18-45 years of age who received a single dose of the test or reference product under fasting conditions. A washout period of 10 d was maintained between period I and period II dosing. After dosing, blood samples were collected from 0 h (pre-dose) to 72 h postdose administration. Lopinavir and ritonavir were quantified using a validated LC-MS/MS method. The data obtained for each subject was evaluated for primary pharmacokinetic variables C(max), AUC(0-72), and AUC(0-Inf) with respect to % ratio and 90% confidence interval for log-transformed data. The 90% confidence intervals (obtained by analysis of variance, ANOVA) were well within the bioequivalence acceptance range of 80% to 125%. Thus, it can be concluded that the evaluated formulations are bioequivalent in terms of rate and extent of absorption. The safety profiles of both the test and reference formulations were comparable.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Lopinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidinones,
http://linkedlifedata.com/resource/pubmed/chemical/Ritonavir,
http://linkedlifedata.com/resource/pubmed/chemical/Tablets
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0004-4172
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
59
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
263-8
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:19537528-Adult,
pubmed-meshheading:19537528-Anti-HIV Agents,
pubmed-meshheading:19537528-Area Under Curve,
pubmed-meshheading:19537528-Chemistry, Pharmaceutical,
pubmed-meshheading:19537528-Cross-Over Studies,
pubmed-meshheading:19537528-Double-Blind Method,
pubmed-meshheading:19537528-Female,
pubmed-meshheading:19537528-Humans,
pubmed-meshheading:19537528-Lopinavir,
pubmed-meshheading:19537528-Male,
pubmed-meshheading:19537528-Pyrimidinones,
pubmed-meshheading:19537528-Quality Control,
pubmed-meshheading:19537528-Ritonavir,
pubmed-meshheading:19537528-Tablets,
pubmed-meshheading:19537528-Therapeutic Equivalency
|
pubmed:year |
2009
|
pubmed:articleTitle |
Bioequivalence study of two fixed dose combination tablet formulations of lopinavir and ritonavir in healthy volunteers.
|
pubmed:affiliation |
Department of Clinical and Bioequivalence Research, Cipla Ltd., Mumbai, India. siddharth.chachad@cipla.com
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|